Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.
about
Clinical and experimental applications of sodium phenylbutyrateScreening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compoundClinical Toxicities of Histone Deacetylase Inhibitors.Histone deacetylase inhibitor therapy in epithelial ovarian cancer.Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancerSodium iodide symporter and the radioiodine treatment of thyroid carcinoma.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.Phenyl acyl acids attenuate the unfolded protein response in tunicamycin-treated neuroblastoma cellsInterpreting clinical assays for histone deacetylase inhibitors.Possible Contribution of Zerumbone-Induced Proteo-Stress to Its Anti-Inflammatory Functions via the Activation of Heat Shock Factor 1.Attenuation of ER stress prevents post-infarction-induced cardiac rupture and remodeling by modulating both cardiac apoptosis and fibrosis.4-PBA prevents pressure overload-induced myocardial hypertrophy and interstitial fibrosis by attenuating endoplasmic reticulum stressHistone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.New perspectives on the treatment of differentiated thyroid cancer.Chromatin, cancer and drug therapies.Beneficial Effects of Sodium Phenylbutyrate Administration during Infection with Salmonella enterica Serovar Typhimurium.Targeting histone deacetylases for the treatment of diseaseThe chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response.New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.The therapeutic potential of chemical chaperones in protein folding diseases.Targeting the unfolded protein response for disease intervention.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.Phenylbutyrate induces apoptosis and lipid accumulations via a peroxisome proliferator-activated receptor gamma-dependent pathway.Study of Antitumor Activity of Sodium Phenylbutyrate, Histon Deacetylase Inhibitor, on Ehrlich Carcinoma Model.Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice.Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents.4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.Activating transcription factor 4 is involved in endoplasmic reticulum stress-mediated apoptosis contributing to vascular calcification.
P2860
Q24613511-5BD25FF7-FBEF-483F-966F-4410FE419058Q28477645-E2890745-3A39-47C8-B12A-869963609E4FQ31135325-31AED649-6972-479C-86EF-B27EDEA1EA33Q33568495-DDA20770-CCA3-443B-8715-DBF1AE52EB5DQ33651762-A1448E3B-FBE6-41E1-951C-09780B5473B0Q33704207-E493FEFF-B5D4-4F4B-B0C5-AAE02964AA73Q33829390-5A3FC68B-08A4-47B8-A8A4-BFC4C195C8D0Q33939797-7CA315F5-369C-4ADF-8E2C-B78853106509Q34970563-16B9F090-F41A-41D0-89C8-08B23163D7D0Q35003657-F44120A2-8E4F-48A8-AD5D-5B3C381F4CEEQ36106637-39F9DD99-BA10-44C0-9C54-DCD03BDA569FQ36384602-384CE6A3-4B72-4B79-ADE8-3BAE4811BC71Q36414916-3BC82022-6455-4DFF-A85A-67658CA058ECQ36654454-7611CA32-1BA4-4D65-9E30-D70B8458E520Q36738957-D074D40F-D5DB-4B19-8E45-3A1D02BAA029Q36904500-44A994C2-95D0-45FB-B9CF-0CAB9AD31128Q37073231-2F6A1E85-DAF2-4D82-942B-42D71C8A3166Q37199789-0C47CC24-013E-447A-A47C-36AE6A1C6B33Q37296159-932AEBB3-6C99-4D2B-A4F2-029111D34C93Q37430626-66733F91-0786-40A6-921C-52779B9FDD84Q37503780-1B4E8003-0822-44CD-A266-725AD5EA060DQ37970955-F89B358E-5453-4C4D-B531-9133EC1BE46CQ38211124-67877F5A-6F3E-47AF-83C2-E10849823F2DQ38545670-CB4DD616-8CCA-4CCF-BE48-CD92BA9A9085Q38572855-0252DFCC-0698-4645-8A24-CA7A64B85EA0Q38844777-3A10295B-18CB-4FC3-8DD4-73EC0D0E9EF7Q39012545-4EF8AA8D-60B6-485C-BFDE-96BC0F073358Q39728530-CDC0081F-BFCC-4C6B-87EF-3F8601AB96F3Q41220433-D259A419-6A48-4453-8DAA-C91D125A4430Q41942519-FF8921D5-2C58-4320-8FD7-98C4A3FC50A3Q47860855-9ACCECEF-3315-4024-B69D-46CF0770F882Q50280122-2E373E70-8A36-4A1E-8055-D1871AAE757FQ50981997-E040C232-73DA-4718-8D69-C10A8A4E0923
P2860
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase I dose escalation clinic ...... ts with advanced solid tumors.
@en
type
label
Phase I dose escalation clinic ...... ts with advanced solid tumors.
@en
prefLabel
Phase I dose escalation clinic ...... ts with advanced solid tumors.
@en
P2093
P1476
Phase I dose escalation clinic ...... ts with advanced solid tumors.
@en
P2093
Charles W Young
David R Spriggs
Mark G Malkin
William P Tong
P2888
P304
P356
10.1007/S10637-006-9017-4
P577
2006-10-20T00:00:00Z
P6179
1018485532